Blasts 5 Percent or More of Bone Marrow Nucleated Cells
4 clinical trials · Condition
◉ Watch Blasts 5 Percent or More of Bone Marrow Nucleated Cells
| Record | Firm | Date |
|---|---|---|
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (NCT03851081) | Roswell Park Cancer Institute | 2021-01-21 |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCT03698552) | M.D. Anderson Cancer Center | 2018-08-24 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia (NCT03519984) | University of Southern California | 2018-05-09 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies (NCT02529813) | M.D. Anderson Cancer Center | 2015-12-16 |
Track Blasts 5 Percent or More of Bone Marrow Nucleated Cells automatically
Every clearance here is in the API, with alerts when new ones post.